2
Clinical Trials associated with GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta) / Not yet recruitingEarly Phase 1IIT GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)
CLIC-YYC-GPNMB-02 is a Single Patient Study (SPS) developed according to the Health Canada template and guidelines released in 2019 for studies to access therapies not otherwise available to patients, in the situation where there are no options of treatment or cure remaining. The patient under consideration for CLIC-YYC-GPNMB-02 has progressive metastatic alveolar soft part sarcoma (ASPS). We propose to treat the patient with GCAR1, a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
/ CompletedEarly Phase 1IIT GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-01)
CLIC-YYC-GPNMB-01 is a Single Patient Study (SPS) developed according to the Health Canada template and guidelines released in 2019 for studies to access therapies not otherwise available to patients, in the situation where there are no options of treatment or cure remaining. The patient under consideration for CLIC-YYC-GPNMB-01 has progressive metastatic alveolar soft part sarcoma (ASPS). The investigators propose to treat the patient with GCAR1, a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
100 Clinical Results associated with GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta)
100 Translational Medicine associated with GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta)
100 Patents (Medical) associated with GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta)
100 Deals associated with GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta)